Skip to main content
Equibles
CYCN logo

CYCN · Korsana Biosciences, Inc. · Metrics

Track CYCN — free

Use CYCN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CYCN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$23.94 -5.81 (-19.53%) At close · Sep 8
Rebalance outlook locked
Going-concern doubt — flagged Aug 4, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern.”
View the 10-Q filed Aug 4, 2026
Market Cap
$2.25M
Shares
668,764

CYCN metrics

55 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$23.94
Market cap
$2.25M

Price action

20 metrics
Price change (1W)
-18.0%
Price change (30D)
-9.8%
Price change (3M)
+14.0%
Price change (6M)
+132.7%
Price change (YTD)
+169.3%
Price change (1Y)
+51.3%
Trailing year
Price change (5Y)
—
52-week high
$44.66
52-week low
$7.56
Change from 52-week high
-46.4%
Change from 52-week low
+216.7%
Annualized volatility
327.9%
Annualized volatility (3M)
77.5%
Beta
2.2
RSI (14D)
42.0
Price vs SMA 50
-8.8%
Price vs SMA 200
+33.6%
Avg volume (3M)
6,577
Relative volume
9.5
Average dollar volume
$174,455

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
668,764

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.2×
reciprocal yield 84.6%
P / book
0.4
reciprocal yield 226.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-298.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-04-01

Profitability

9 metrics
Gross margin
—
Operating margin
-239.8%
Trailing 12 months
Net margin
-170.1%
Gross profit (TTM)
—
Operating profit (TTM)
−$6.82M
Net income (TTM)
−$6.71M
Trailing 12 months
Diluted EPS (TTM)
$-11.27
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$16.64

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.90M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+38.4%
Year over year · more shares
Revenue CAGR (3Y)
+91.1%
Revenue CAGR (5Y)
-2.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-131.8%
Return on assets
-96.8%
Debt / equity
—
Current ratio
0.8
EBITDA (TTM)
−$12.95M
Free cash flow (TTM)
—
Quick ratio
0.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$1.39M
Total assets
$6.93M
Total debt
$3.50M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$4.45M
Capital expenditures (TTM)
—
R&D (TTM)
$1.60M
SG&A (TTM)
—
Stock compensation (TTM)
$322,000
R&D / revenue
84.1%
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
21
13F filer change QoQ
+4
Institutional ownership
70.5%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1755237 CUSIP 23255M204 13F (30d) 10 filings 10 filers Visit website Investor relations